120 related articles for article (PubMed ID: 8833970)
1. Estimation of impurity profiles of drugs and related materials. Part 14: the role of HPLC/diode-array UV spectroscopy in the identification of minor components (impurities, degradation products, metabolites) in various matrices.
Görög S; Bihari M; Csizér E; Dravetz F; Gazdag M; Herényi B
J Pharm Biomed Anal; 1995 Dec; 14(1-2):85-92. PubMed ID: 8833970
[TBL] [Abstract][Full Text] [Related]
2. Analysis of steroids. XXXVIII. The use of high-performance liquid chromatography with diode-array UV detection for estimating impurity profiles of steroid drugs.
Görög S; Herényi B
J Chromatogr; 1987 Jul; 400():177-86. PubMed ID: 3667745
[TBL] [Abstract][Full Text] [Related]
3. The changing role of ultraviolet spectroscopy in drug analysis.
Görög S; Rényei M; Herényi B
J Pharm Biomed Anal; 1989; 7(12):1527-33. PubMed ID: 2490539
[TBL] [Abstract][Full Text] [Related]
4. Estimation of impurity profiles of drugs and related materials: part 19: theme with variations. Identification of impurities in 3-oxosteroids.
Görög S; Babják M; Balogh G; Brlik J; Dravecz F; Gazdag M; Horváth P; Laukó A; Varga K
J Pharm Biomed Anal; 1998 Dec; 18(4-5):511-25. PubMed ID: 9919951
[TBL] [Abstract][Full Text] [Related]
5. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
Görög S
Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
[TBL] [Abstract][Full Text] [Related]
6. Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate.
Babják M; Balogh G; Gazdag M; Görög S
J Pharm Biomed Anal; 2002 Aug; 29(6):1153-7. PubMed ID: 12110402
[TBL] [Abstract][Full Text] [Related]
7. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
8. Active drug substance impurity profiling part I. LC/UV diode array spectral matching.
Nicolas EC; Scholz TH
J Pharm Biomed Anal; 1998 Jan; 16(5):813-24. PubMed ID: 9535194
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of steroids. Part 42. By-products of the ethynylation of 17-ketosteroids (isolation, identification and determination)].
Laukó A; Csehi A; Balogh G; Csizér E; Herényi B; Görög S
Acta Pharm Hung; 1991 Mar; 61(2):98-104. PubMed ID: 1887805
[TBL] [Abstract][Full Text] [Related]
10. Estimation of impurity profiles in drugs and related materials. Part 11--The role of chromatographic and spectroscopic methods in the estimation of side-reactions in drug syntheses.
Görög S; Balogh G; Csehi A; Csizér E; Gazdag M; Halmos Z; Hegedüs B; Herényi B; Horváth P; Laukó A
J Pharm Biomed Anal; 1993; 11(11-12):1219-26. PubMed ID: 8123737
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
[TBL] [Abstract][Full Text] [Related]
12. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection.
Xue G; Bendick AD; Chen R; Sekulic SS
J Chromatogr A; 2004 Oct; 1050(2):159-71. PubMed ID: 15508308
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of FDG, ClDG and Kryptofix 2.2.2 in [18F]FDG preparation by high-performance liquid chromatography with UV detection.
Nakao R; Ito T; Yamaguchi M; Suzuki K
Nucl Med Biol; 2008 Feb; 35(2):239-44. PubMed ID: 18312835
[TBL] [Abstract][Full Text] [Related]
14. Estimation of impurity profiles of drugs and related materials Part 18. Impurities and degradation products of mazipredone.
Gazdag M; Babják M; Brlik J; Mahó S; Tuba Z; Görög S
J Pharm Biomed Anal; 1998 Sep; 17(6-7):1029-36. PubMed ID: 9884192
[TBL] [Abstract][Full Text] [Related]
15. A digitized impurity database analysis method for determining the impurity profiles of gatifloxacin in bulk materials and injections.
Dousheng Z; Yan C; Yaping L; Shangchen Y; Changqin H
Pharmazie; 2012 Oct; 67(10):827-33. PubMed ID: 23136715
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
[TBL] [Abstract][Full Text] [Related]
17. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.
Chen Y; Brill GM; Benz NJ; Leanna MR; Dhaon MK; Rasmussen M; Zhou CC; Bruzek JA; Bellettini JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):106-17. PubMed ID: 17826364
[TBL] [Abstract][Full Text] [Related]
18. The use of ultraviolet spectra and chromatographic retention data as an aid to metabolite identification.
Law B; Stafford LE
J Pharm Biomed Anal; 1993 Aug; 11(8):729-36. PubMed ID: 8257738
[TBL] [Abstract][Full Text] [Related]
19. Estimation of impurity profiles of drugs and related materials. 12. Isolation and identification of an isomeric impurity in danazol.
Balogh G; Csizér E; Ferenczy GG; Halmos Z; Herényi B; Horváth P; Laukó A; Görög S
Pharm Res; 1995 Feb; 12(2):295-8. PubMed ID: 7784348
[TBL] [Abstract][Full Text] [Related]
20. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
